

Logo of participating institution 1



Logo of participating institution 2

COUNTRY

Name of institution(s) participating in PPRI

Challenges and developments of the year 2009

- Major developments / challenges, in particular in the light of the financial crisis
- In connection with any court laws, infringement procedures
- Launch / continuation of talks, dialogues, discussion with companies or other stakeholders
- Campaigns to the public, further initiatives
- Development of expenditure / volume

Changes in 2010 (planned or discussed)

Pricing

- Regarding pricing policies (e.g. statutory pricing, price negotiations, free pricing) for pharmaceuticals (for all / reimbursable ph.), at which type of price (e.g. ex-factory price, wholesale price)
- Regarding pricing methods (e.g. external price referencing), criteria for pricing decisions
- Composition / role of pricing bodies
- Regarding wholesale mark up (for all / reimbursable pharmaceuticals), linear/regressive
- Regarding pharmacy mark up (for all / reimbursable pharmaceuticals), linear/regressive
- Regarding VAT rate (on pharmaceuticals, standard rate)

Reimbursement

- Introduction / extension / limitation of the positive / negative list (e.g. de-listings)
- Reviews of the positive / negative list
- Changes in the reimbursement rates for pharmaceuticals on the positive list
- Reimbursement decision-making bodies
- Introduction of a reference price system, changes in the methodology (cluster, reference price)
- Regarding the co-payment (e.g. prescription fee, percentage co-payment)

Rational use and other areas

- Measures targeted at doctors (e.g. INN prescribing, pharmaceutical budgets, targets for prescribing, prescription monitoring, platform for dialogue)
- Measures targeted at pharmacists (e.g. generics substitution, targets for substitution)
- Measures targeted at patients (e.g. information campaign on generics)
- Information to patients (e.g. change in promotion laws)
- Vigilance